AtriCure Q2 revenue beats estimates

AtriCure

23/07/2026 21:11

    

    Overview
  
U.S. surgical device maker's Q2 revenue grew 13%, beating analyst expectations
Adjusted EPS for Q2 beat consensus at $0.18
Adjusted EBITDA rose 78% yr/yr, beating analyst expectations

    

    Outlook
  
AtriCure projects 2026 revenue of $602 mln to $610 mln
Company expects 2026 adjusted EBITDA of $85 mln to $89 mln
AtriCure sees 2026 net income per share at $0.05 to $0.13 and adjusted EPS at $0.24 to $0.32

    

    Result Drivers
  
PAIN MANAGEMENT GROWTH - Sales of cryoSPHERE MAX probe for post-operative pain management drove U.S. revenue growth
APPENDAGE MANAGEMENT DEVICES - Higher sales of AtriClip FLEX-Mini and PRO-Mini devices contributed to revenue gains
GROSS MARGIN IMPROVEMENT - Gross margin rose due to favorable product and geographic mix and manufacturing efficiencies

    
Company press release: ID:nBw79hrlFa

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
Q2 Revenue
Beat
$153.6 mln
$151.84 mln (9 Analysts)
Q2 Adjusted EPS
Beat
$0.18
$0.004 (9 Analysts)
Q2 Adjusted EBITDA
Beat
$27.3 mln
$19.94 mln (8 Analysts)
Q2 Gross Margin
 
77.2%
 
Q2 Gross Profit
 
$118.6 mln
 
Q2 Operating Income
 
$9.7 mln
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for AtriCure Inc is $50.00, about 49.2% above its July 22 closing price of $33.52
The stock recently traded at 157 times the next 12-month earnings vs. a P/E of 231 three months ago

    

    Reuters Recommended Reads
  
July 23 - Novocure Q2 revenue beats, lifts 2026 outlook
July 23 - Utah Medical Q2 revenue falls 14% on lost customers
July 21 - PolyPid, Azurity sign surgical site infection drug deal

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)